China M&A roundup: construction-software buyer pushes into Singapore; veteran drugmaker eyes control of Changzhou No.4 Pharmaceutical (常州四药)

A leading Chinese construction software firm is reportedly buying a Singapore-based company for about RMB 34.31 million, it has been reported that the move is designed to accelerate its push into Southeast Asia. Meanwhile, a veteran domestic pharmaceutical group has submitted a letter of intent to take control of Changzhou No.4 Pharmaceutical (常州四药), signaling consolidation in China’s mid‑market pharma sector. Both items appear in the latest M&A Frontline roundup and value analysis as of April 13.

Cross‑border push into Southeast Asia

It has been reported that the construction‑software buyer—which describes itself as a market leader in digital project management and BIM (building information modelling) tools—will pay roughly RMB 34.31 million for the Singapore target. The deal is positioned as a strategic foothold in ASEAN markets where Chinese software vendors have been competing on pricing and local partnerships; why expand now? Firms say regional construction demand and infrastructure spending make Southeast Asia an attractive near‑term growth corridor.

Domestic pharma consolidation

Reportedly, a long‑established Chinese pharmaceutical firm has submitted an LOI to acquire controlling stakes in Changzhou No.4 Pharmaceutical (常州四药). Details on price and financing were not disclosed in initial reports. The planned takeover fits a broader trend of legacy Chinese drugmakers pursuing scale and portfolio rationalization amid tougher regulatory scrutiny and pricing pressure at home.

Market and geopolitical context

These deals come as Chinese companies recalibrate growth strategies amid slowing domestic demand, supply‑chain shifts and heightened geopolitical scrutiny of cross‑border investments. While acquisitions in Southeast Asia face fewer direct sanctions than deals involving Western tech, investors still weigh trade policy and regulatory risks. It has been reported that dealmakers are increasingly favoring smaller, bolt‑on acquisitions that offer immediate market access rather than large, high‑profile trophies.